MX306302B - Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - Google Patents

Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli

Info

Publication number
MX306302B
MX306302B MX2007010043A MX2007010043A MX306302B MX 306302 B MX306302 B MX 306302B MX 2007010043 A MX2007010043 A MX 2007010043A MX 2007010043 A MX2007010043 A MX 2007010043A MX 306302 B MX306302 B MX 306302B
Authority
MX
Mexico
Prior art keywords
meningitis
sepsis
proteins
nucleic acids
escherichia coli
Prior art date
Application number
MX2007010043A
Other languages
English (en)
Spanish (es)
Other versions
MX2007010043A (en
Inventor
Laura Serino
Vega Masignani
Herve Tettelin
Mariagrazia Pizza
Francesco Berlanda Scorza
Original Assignee
Inst Genomic Research
Novartis Vaccines & Diagnostic
Francesco Berlanda Scorza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Genomic Research, Novartis Vaccines & Diagnostic, Francesco Berlanda Scorza filed Critical Inst Genomic Research
Publication of MX2007010043A publication Critical patent/MX2007010043A/es
Publication of MX306302B publication Critical patent/MX306302B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2007010043A 2005-02-18 2007-08-17 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli MX306302B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65463205P 2005-02-18 2005-02-18
US71272005P 2005-08-29 2005-08-29

Publications (2)

Publication Number Publication Date
MX2007010043A MX2007010043A (en) 2008-08-29
MX306302B true MX306302B (en) 2012-12-19

Family

ID=36917149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010043A MX306302B (en) 2005-02-18 2007-08-17 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli

Country Status (18)

Country Link
US (4) US8758764B2 (https=)
EP (2) EP2351772B1 (https=)
JP (2) JP2008529558A (https=)
AU (1) AU2006214064B2 (https=)
CA (1) CA2601924A1 (https=)
CY (2) CY1117732T1 (https=)
DK (2) DK2351772T3 (https=)
ES (2) ES2595363T3 (https=)
HU (2) HUE030881T2 (https=)
IL (2) IL185359A0 (https=)
LT (1) LT2351772T (https=)
MX (1) MX306302B (https=)
NZ (3) NZ597685A (https=)
PL (2) PL1858920T3 (https=)
PT (1) PT2351772T (https=)
SG (1) SG160329A1 (https=)
SI (2) SI2351772T1 (https=)
WO (1) WO2006089264A2 (https=)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
DK1328543T3 (da) * 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
ITMI20081249A1 (it) * 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
JP5332237B2 (ja) * 2008-03-06 2013-11-06 味の素株式会社 Ｌ−システイン生産菌及びｌ−システインの製造法
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
WO2010124085A2 (en) * 2009-04-23 2010-10-28 Cornell University Compositions and methods for preventing and treating uterine disease
WO2010129578A1 (en) * 2009-05-06 2010-11-11 Cornell Research Foundation, Inc. E. coli lpfa antigen for prevention and treatment of infectious diseases
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
PL2464658T3 (pl) 2009-07-16 2015-03-31 Novartis Ag Immunogeny z Escherichia coli o zniesionej toksyczności
EP2277989A1 (en) 2009-07-24 2011-01-26 Technische Universiteit Delft Fermentative glycerol-free ethanol production
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
ES2387719T3 (es) * 2009-09-10 2012-09-28 Freie Universität Berlin Identificación y caracterización de una nueva adhesina fimbrial de E. coli patógena aviar (APEC)
DK2482836T3 (en) * 2009-10-02 2016-06-06 Univ Oslo Hf Antibacterial polypeptides and the use thereof
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
EP2509961B1 (en) 2009-12-11 2016-03-09 Autifony Therapeutics Limited Imidazolidinedione derivatives
JP5781542B2 (ja) * 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
RS63817B1 (sr) 2010-07-06 2023-01-31 Glaxosmithkline Biologicals Sa Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
PT3970742T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
ES2727583T3 (es) 2010-08-31 2019-10-17 Glaxosmithkline Biologicals Sa Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
BR112013005626B1 (pt) * 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
EP3508220A1 (en) 2011-08-31 2019-07-10 GlaxoSmithKline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding rna
WO2013038385A2 (en) 2011-09-14 2013-03-21 Novartis Ag Escherichia coli vaccine combination
KR101359844B1 (ko) * 2012-01-06 2014-02-25 씨제이제일제당 (주) 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법
JP5961635B2 (ja) * 2012-01-18 2016-08-02 三井化学株式会社 １、５−ペンタメチレンジアミンの製造方法
MX346678B (es) 2012-03-07 2017-03-29 Novartis Ag Sales de arginina utiles inmunologicamente.
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
CN104812773B (zh) * 2012-07-20 2018-04-06 庆熙大学校产学协力团 表位标记用抗体、杂交瘤细胞株以及其用途
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
DK2909334T3 (da) * 2012-10-17 2020-09-28 Enterome Gensignaturer af inflammatoriske lidelser, som er relateret til leveren og Crohns sygdom
US10288610B2 (en) * 2012-11-13 2019-05-14 The General Hospital Corporation Vitro assays for detecting Salmonella enterica serotype typhi
WO2014102694A1 (en) 2012-12-24 2014-07-03 Novartis Ag Novel mucinase for use in therapy or prophylaxis
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
AU2014227653B2 (en) 2013-03-15 2017-04-20 The General Hospital Corporation Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
KR101525663B1 (ko) * 2013-05-10 2015-06-04 씨제이제일제당 (주) 신규 ｏ-포스포세린 배출 단백질 및 이를 이용한 ｏ-포스포세린의 생산방법
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
EP3027205A4 (en) * 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
KR20150018227A (ko) * 2013-08-09 2015-02-23 삼성전자주식회사 외인성 푸마라아제 유전자를 포함하는 코리네박테리움 및 이를 이용한 c4 디카르복실산의 생산 방법
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
AU2015227075A1 (en) * 2014-03-06 2016-09-22 Ohio State Innovation Foundation Probiotic formulations and methods for use
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
US10125092B2 (en) 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
CN107771214B (zh) * 2015-04-07 2022-01-18 代谢探索者公司 用于具有增加的2,4-二羟基丁酸外排物的优化的2,4-二羟基丁酸产生的修饰的微生物
US20160317615A1 (en) * 2015-05-01 2016-11-03 Jose Javier Lopez GONZALEZ T cell modulator
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11209972B2 (en) 2015-09-02 2021-12-28 D&M Holdings, Inc. Combined tablet screen drag-and-drop interface
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
US11702636B2 (en) 2015-11-16 2023-07-18 National University Corporation Kumamoto University Composition inducing cell reprogramming and production method for multifunction cells using said composition
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
WO2017127731A1 (en) * 2016-01-21 2017-07-27 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of bacteria
US11155578B2 (en) 2016-02-17 2021-10-26 Pepticom Ltd. Peptide agonists and antagonists of TLR4 activation
US11248270B2 (en) * 2016-03-14 2022-02-15 The Translational Genomics Research Institute Methods and kits to identify Klebsiella strains
CN108884483A (zh) * 2016-03-16 2018-11-23 帝斯曼知识产权资产管理有限公司 烟酸核糖苷的微生物生产
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
GB201617548D0 (en) * 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
WO2018200894A1 (en) 2017-04-28 2018-11-01 Intrexon Corporation Methods and microorganisms for the fermentation of methane to multi-carbon compounds
KR101943081B1 (ko) * 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
WO2019147743A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
EP3821026A4 (en) 2018-07-09 2022-06-01 Codexis, Inc. MANIPULATED ENZYME VARIANTS OF PHOSPHOPENTOMUTASE
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
JP7541513B2 (ja) * 2018-10-05 2024-08-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
SG11202103001PA (en) 2018-10-05 2021-04-29 Res Inst Nationwide Childrens Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
US12569524B2 (en) 2018-10-22 2026-03-10 Research Institute At Nationwide Children's Hospital Compositions and methods for preventing and treating antibiotic induced pathologies using probiotics in the biofilm state
KR101991207B1 (ko) 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101996767B1 (ko) * 2018-11-29 2019-07-04 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101991206B1 (ko) * 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
WO2020123569A1 (en) * 2018-12-10 2020-06-18 Flagship Pioneering Innovations Vi, Llc Achromosomal dynamic active systems
US20220211872A1 (en) * 2019-05-15 2022-07-07 Universidad De Granada Gene therapy with the genes hokd and ldrb for cancer treatments
WO2020247536A1 (en) 2019-06-03 2020-12-10 Research Institute At Nationwide Children's Hospital Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
US10920189B2 (en) * 2019-06-21 2021-02-16 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli
CN110441284B (zh) * 2019-07-23 2022-02-15 海南大学 一种可用于痕量检测的表面增强拉曼散射芯片的制备方法及所得产品和应用
KR102183209B1 (ko) * 2019-09-09 2020-11-26 씨제이제일제당 주식회사 L-쓰레오닌 배출 단백질의 변이체 및 이를 이용한 l-쓰레오닌 생산 방법
WO2021085405A1 (ja) * 2019-10-28 2021-05-06 味の素株式会社 ベンズアルデヒドの製造方法
KR20220119408A (ko) * 2019-12-20 2022-08-29 바스프 에스이 터펜의 독성 감소 및 미생물에서 생산 잠재성 증가
US20230105474A1 (en) * 2020-02-25 2023-04-06 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
CN111778224B (zh) * 2020-07-20 2021-06-01 成都薇合生物科技有限公司 尿酸酶或其同源酶及其应用
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
EP4225909A4 (en) * 2020-10-07 2025-02-12 Codexis, Inc. Engineered phosphopentomutase variant enzymes
CN112391331B (zh) * 2020-11-12 2022-09-27 江南大学 一种过表达GatA基因的重组大肠杆菌及其应用
KR102792504B1 (ko) * 2020-12-28 2025-04-09 대상 주식회사 히스티딘에 의한 피드백 억제가 감소된 atp-prt 변이체 및 이를 발현하는 히스티딘 생산 균주
CN114137209B (zh) * 2021-02-01 2024-03-01 中国水产科学研究院黄海水产研究所 一种快速检测牡蛎疱疹病毒抗原的免疫荧光检测试纸条及应用
US11452757B2 (en) * 2021-02-25 2022-09-27 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
KR20230164108A (ko) 2021-04-01 2023-12-01 얀센 파마슈티칼즈, 인코포레이티드 E. coli O18 생물접합체의 생산
KR102707457B1 (ko) * 2021-06-11 2024-09-20 씨제이제일제당 주식회사 신규한 MdtH 변이체 및 이를 이용한 O-포스포세린, 시스테인 및 이의 유도체의 생산방법
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023021427A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
US20250137050A1 (en) * 2021-08-18 2025-05-01 The Regents Of The University Of California Methods and compositions for determining risk of autism spectrum disorders
CN113897324B (zh) * 2021-10-13 2023-07-28 云南师范大学 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法
CN114107413B (zh) * 2021-11-03 2023-10-20 江苏香地化学有限公司 一种酶催化胞嘧啶生产胞苷的方法及应用
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
US12516086B2 (en) 2021-12-21 2026-01-06 Sri International Dual targeting for cell-specific delivery to the central nervous system
CN114522230A (zh) * 2022-01-11 2022-05-24 上海市伤骨科研究所 一种蓝光和对苯醌联合杀菌方法
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN115286701A (zh) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用
WO2023245129A2 (en) * 2022-06-15 2023-12-21 Quantum-Si Incorporated Directed protein evolution
WO2024073730A2 (en) * 2022-09-29 2024-04-04 The University Of Chicago Methods and systems for rna sequencing and analysis
AU2023362022A1 (en) 2022-10-19 2025-05-01 Glyprovac Aps Glycosylated yghj polypeptides from uropathogenic e. coli
CN118086235A (zh) * 2022-11-28 2024-05-28 宁波酶赛生物工程有限公司 一种合成d-泛解酸的酶催化剂和方法
KR102921214B1 (ko) * 2023-01-31 2026-02-03 대상 주식회사 망가니즈 익스포터 신규 변이체 및 이를 이용한 l-히스티딘 생산 방법
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
WO2025017339A1 (en) * 2023-07-14 2025-01-23 Iowa State University Research Foundation, Inc. Escherichia coli nhaa membrane protein drug target and immunogenic compositions therefrom
CN116949027B (zh) * 2023-07-19 2024-12-24 浙江中医药大学 一种尿路致病性大肠埃希菌重组蛋白组合物ls、其构建、表达、纯化方法及其应用
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
WO2025219177A1 (en) 2024-04-18 2025-10-23 Glyprovac Aps Optimized plasmids for expression of yghj polypeptides
CN118388664B (zh) * 2024-05-21 2024-12-03 广东省农业科学院动物卫生研究所 副猪嗜血杆菌融合抗原及其应用
WO2026033498A1 (en) 2024-08-09 2026-02-12 Genvax Technologies, Inc. Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom
CN119061031A (zh) * 2024-10-08 2024-12-03 安徽农业大学 一种水稻抗除草剂突变基因及其应用

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
CA2289219C (en) 1991-03-01 2003-05-20 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1h-imidazo[4,5-c]quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
EP0708772B1 (en) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU6489996A (en) 1995-07-14 1997-02-18 Somatogen, Inc. Methods for increasing protein expression
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
EP0942964A2 (en) 1996-11-22 1999-09-22 Human Genome Sciences, Inc. Thermostable polymerases having altered fidelity
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
IL137809A0 (en) 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1105495B2 (en) 1998-08-14 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Method for producing yeast expressed hpv types 6 and 16 capsid proteins
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
WO2002016439A2 (en) 2000-03-07 2002-02-28 Hyseq, Inc. Novel nucleic acids and polypeptides
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
DE60039198D1 (de) 1999-03-26 2008-07-24 Vical Inc Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CN101033467A (zh) 1999-04-30 2007-09-12 希龙公司 奈瑟球菌基因组序列及其用法
AU5561599A (en) 1999-05-05 2000-11-21 Sterrenbeld Biotechnologie North America, Inc. Dna promoter sequence for gene expression
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
CZ20021043A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
EP1328641A2 (en) 2000-03-10 2003-07-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
EP1313734B1 (en) 2000-09-01 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Aza heterocyclic derivatives and their therapeutic use
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AU2002246592A1 (en) 2000-10-19 2002-08-06 Wisconsin Alumni Research Foundation Dna sequences of escherichia coli cft073
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
DE60238471D1 (de) 2001-03-09 2011-01-13 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
EA008380B1 (ru) 2001-11-27 2007-04-27 Анадис Фармасьютикалз, Инк. 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US20030165870A1 (en) 2002-03-01 2003-09-04 Blattner Frederick R. Novel sequences of E. coli CFT073
EP1342784A1 (en) 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
NZ535985A (en) 2002-03-29 2007-04-27 Chiron Corp Substituted benzazoles and use thereof as RAF kinase inhibitors
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
FR2842210B1 (fr) 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
AU2003268184A1 (en) 2002-08-23 2004-03-11 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US20040209370A1 (en) 2002-12-19 2004-10-21 Wonchul Suh Method for chromosomal engineering
CA2511646A1 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP1441036A1 (en) 2003-01-27 2004-07-28 Université de Nantes Method for the identification and isolation of strong bacterial promoters
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
JP4049045B2 (ja) 2003-07-28 2008-02-20 トヨタ自動車株式会社 蓄熱装置付きエンジンシステム
EP1721283B1 (en) * 2004-02-06 2022-11-30 Council of Scientific and Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
CA2557353A1 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli

Also Published As

Publication number Publication date
SI1858920T1 (sl) 2016-07-29
DK1858920T3 (en) 2016-02-29
IL185359A0 (en) 2008-02-09
CY1117732T1 (el) 2017-05-17
US8758764B2 (en) 2014-06-24
HUE027400T2 (en) 2016-10-28
CY1118149T1 (el) 2017-06-28
WO2006089264A8 (en) 2008-03-06
US10035826B2 (en) 2018-07-31
HUE030881T2 (en) 2017-06-28
LT2351772T (lt) 2016-10-10
JP2008529558A (ja) 2008-08-07
ES2569654T3 (es) 2016-05-12
EP2351772B1 (en) 2016-07-13
EP1858920B1 (en) 2016-02-03
EP2351772A1 (en) 2011-08-03
US9334313B2 (en) 2016-05-10
US20140356389A1 (en) 2014-12-04
US20080193470A1 (en) 2008-08-14
NZ561042A (en) 2011-03-31
US20160244489A1 (en) 2016-08-25
DK2351772T3 (en) 2016-09-05
PL2351772T3 (pl) 2017-01-31
MX2007010043A (en) 2008-08-29
IL206012A0 (en) 2010-11-30
ES2595363T3 (es) 2016-12-29
PT2351772T (pt) 2016-09-22
SI2351772T1 (sl) 2016-11-30
PL1858920T3 (pl) 2016-12-30
CA2601924A1 (en) 2006-08-24
SG160329A1 (en) 2010-04-29
AU2006214064A1 (en) 2006-08-24
JP2012152228A (ja) 2012-08-16
WO2006089264A2 (en) 2006-08-24
US20180298064A1 (en) 2018-10-18
NZ597685A (en) 2013-12-20
WO2006089264A3 (en) 2007-04-05
AU2006214064B2 (en) 2012-04-26
NZ597769A (en) 2013-09-27
EP1858920A2 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
MX306302B (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
IL185547A0 (en) Lipocalin protein
EP1856291A4 (en) NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
IL188611A (en) Type 1sp polypeptides are altered at the n-terminal end and used
EP2061884A4 (en) SENSOR PROTEINS AND TEST PROCEDURES THEREFOR
EP1725661A4 (en) POLYNUCLEOTIDE FOR THE DETECTION OF SCHERICHIA COLI O157
GB0507537D0 (en) Protein resistant surfaces
IL193699A0 (en) Proteins, nucleic acids and medicaments
EP1666588A4 (en) NOVEL TRANSPORTED PROTEIN
IL173764A0 (en) Amino acids with affinity for the alpha2delta-protein
GB0514482D0 (en) Protein
HK1111175A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0724832D0 (en) Proteins and nucleic acids
EP1925670A4 (en) HIGH EXPRESSION ESCHERICHIA COLI VECTOR AND USES THEREOF
EP1759000A4 (en) POLYNUCLEOTIDES FOR DETECTION OF ESCHERICHIA COLI
GB0522113D0 (en) vWFA-domain containing proteins
GB0513505D0 (en) Proteins
GB0514481D0 (en) Proteins
GB0514788D0 (en) Proteins
GB0518460D0 (en) Protein assay
GB0513561D0 (en) Protein
GB0515438D0 (en) Protein
GB0504075D0 (en) Plac-1-like protein
GB0514789D0 (en) Protein
GB0514718D0 (en) Protein

Legal Events

Date Code Title Description
FG Grant or registration